A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
Stopped Per protocol stopping rule was met. Comprehensive review is needed prior to resuming enrollment.
Conditions
- Developmental and Epileptic Encephalopathy
Interventions
Sponsor
Capsida Biotherapeutics, Inc.